Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.A treatment of hepatocellular carcinoma, to be advanced in human trials
Subscribe to our email newsletter
Nymox has reported that NX-1207 has showed positive results when given to animals with hepatocellular carcinoma (HCC). NX-1207 is a novel drug in phase 3 development, for the treatment of benign prostatic hyperplasia (BPH).
The company said that in the experimental studies, cancers were significantly reduced in size after two local injections of NX-1207. The rodents in the studies had transplanted human HCC. These animals had an average tumor burden reduction of close to 50% after 20 days.
The company further plans to advance NX-1207 into human clinical trials for the treatment of HCC.
Moreover, the drug has been successful in a series of blinded controlled multi-center US clinical trials, where it has been found to produce improvements that are about double than reported for currently approved BPH drugs.
Follow-up studies have shown that many men showed continued benefit from a single NX-1207 treatment for two years or more.